health
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
TL;DR
- Eli Lilly announced plans to acquire three companies for nearly $4 billion to expand into infectious disease R&D.
- The companies being acquired are Curevo ($1.5 billion), LimmaTech Biologics ($780 million), and Vaccine Company ($1.55 billion).
- Acquisitions focus on preventing diseases, including vaccines for shingles, treatments for bacterial pathogens, and technologies for viral pathogens.
- Curevo developed a shingles vaccine with improved tolerability and reduced side effects.
- LimmaTech targets bacterial pathogens like those causing STIs, addressing antimicrobial drug resistance.
- Vaccine Company is developing In Vivo Nanoparticle (IVN) technologies to deliver drugs and combat viral pathogens, including Epstein-Barr Virus.
- Eli Lilly is also a major player in the weight loss and diabetes drug market, facing competition from Novo Nordisk.